Waiting for breakout in Crispr Therapeutics

• 
  

Bullish channel devolved and a perfect retrace complete.
Large time-frame you will see a massive Cup and Handle pattern developing
Average analysts price target $74 | Overweight
Short interest 9%
Company profile
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, and Shaun Patrick Foy in 2014 and is headquartered in Zug, Switzerland.

Комментарий:

Комментарий: